Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Clinical trial NCT03552692 · TERMINATED
Trial details
- NCT number
- NCT03552692
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-25
- Primary completion
- 2020-03-04
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.